Screener
Palvella Therapeutics PVLA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Derivative liabilities – contingent value right liability | — | 2,196 |
| Current portion of operating lease liability | 209 | 202 |
| Accrued expenses and other current liabilities | 3,463 | 4,351 |
| Total current liabilities | 9,115 | 11,344 |
| Long-term portion of operating lease liability | 375 | 431 |
| Royalty agreement liability | 19,799 | 17,760 |
| Derivative liabilities – royalty agreement | 2,157 | 2,041 |
| Total liabilities | 31,446 | 31,576 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's total current liabilities?
- Palvella Therapeutics (PVLA) reported total current liabilities of $9.12M in Q1 2026.
- How has Palvella Therapeutics's total current liabilities changed year-over-year?
- Palvella Therapeutics's total current liabilities increased by 1.5% year-over-year, from $8.98M to $9.12M.
- What is the long-term trend for Palvella Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Palvella Therapeutics's total current liabilities has grown at a -12.5% compound annual growth rate (CAGR), from $22.15M to $11.34M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Palvella Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude